Leukapheresis for CAR-T cell production and therapy

Pessach, Ilias; Nagler, Arnon

doi:10.1016/j.transci.2023.103828

Search citation statements

Order By: Relevance

Paper Sections

Select...

Production Of Car-t Cells1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leukapheresis is used to obtain healthy white blood cells to treat patients by chimeric antigen receptor (CAR)-T cells. Most CAR-T cells are produced from autologous peripheral blood mononuclear cells (PBMCs), followed by T cell selection, activation, gene modification, and expansion ( 7 ). The T cells are reprogrammed by genetic modification that may involve introducing a genetic sequence through a lentiviral vector so that the T cells produce surface receptors called CARs.…”

Section: Production Of Car-t Cellsmentioning

confidence: 99%

Reprogramming T cells as an emerging treatment to slow human age-related decline in health

Peplow

2024

Front. Med. Technol.

View full text Add to dashboard Cite

show abstract

Section: Production Of Car-t Cellsmentioning

confidence: 99%

Reprogramming T cells as an emerging treatment to slow human age-related decline in health

Peplow

2024

Front. Med. Technol.

View full text Add to dashboard Cite

show abstract

Cryopreservation of Immune Cells: Recent Progress and Challenges Ahead

Qi,

Jia,

Zhou

et al. 2024

Advanced Biology

View full text Add to dashboard Cite

Cryopreservation of immune cells is considered as a key enabling technology for adoptive cellular immunotherapy. However, current immune cell cryopreservation technologies face the challenges with poor biocompatibility of cryoprotection materials, low efficiency, and impaired post‐thaw function, limiting their clinical translation. This review briefly introduces the adoptive cellular immunotherapy and the approved immune cell‐based products, which involve T cells, natural killer cells and etc. The cryodamage mechanisms to these immune cells during cryopreservation process are described, including ice formation related mechanical and osmotic injuries, cryoprotectant induced toxic injuries, and other biochemical injuries. Meanwhile, the recent advances in the cryopreservation medium and freeze‐thaw protocol for several representative immune cell type are summarized. Furthermore, the remaining challenges regarding on the cryoprotection materials, freeze‐thaw protocol, and post‐thaw functionality evaluation of current cryopreservation technologies are discussed. Finally, the future perspectives are proposed toward advancing highly efficient cryopreservation of immune cells.

show abstract

Biotechnology Advances in Disease Treatment

Banesh,

Sevda

2025

International Encyclopedia of Public Health

View full text Add to dashboard Cite

Leukapheresis for CAR-T cell production and therapy

Cited by 6 publications

References 138 publications

Reprogramming T cells as an emerging treatment to slow human age-related decline in health

Reprogramming T cells as an emerging treatment to slow human age-related decline in health

Cryopreservation of Immune Cells: Recent Progress and Challenges Ahead

Biotechnology Advances in Disease Treatment

Contact Info

Product

Resources

About